Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Buys 20,000 Shares of Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Ingmar Bruns purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Zentalis Pharmaceuticals Stock Up 3.8 %

NASDAQ:ZNTL traded up $0.08 on Wednesday, hitting $2.16. The stock had a trading volume of 938,298 shares, compared to its average volume of 2,729,571. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.61 and a 52 week high of $18.07. The business’s fifty day moving average is $2.72 and its 200 day moving average is $3.15. The company has a market cap of $153.93 million, a PE ratio of -0.87 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ZNTL shares. Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Wells Fargo & Company decreased their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, HC Wainwright decreased their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.24.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after purchasing an additional 5,333 shares in the last quarter. Carson Advisory Inc. lifted its holdings in Zentalis Pharmaceuticals by 55.8% during the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after acquiring an additional 8,800 shares during the period. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the third quarter worth $37,000. Paloma Partners Management Co bought a new stake in Zentalis Pharmaceuticals during the third quarter worth $37,000. Finally, 49 Wealth Management LLC lifted its holdings in Zentalis Pharmaceuticals by 81.7% during the third quarter. 49 Wealth Management LLC now owns 22,558 shares of the company’s stock worth $83,000 after acquiring an additional 10,145 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.